Phase IV: Randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults

Joon-Young Song, Hee-Jin Cheong, Jacob Lee, Seong Heon Wie, Kyung Hwa Park, Sae Yoon Kee, Hye Won Jeong, Yeon Sook Kim, Ji Yun Noh, Wonseok Choi, Dae Won Park, Jang Wook Sohn, Woo Joo Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Influenza vaccines are the primary method for preventing influenza and its complications. Considering the increasing demand for influenza vaccines, vaccine manufacturers are required to establish large-scale production systems. This phase IV randomized trial was conducted to evaluate the lot consistency of trivalent split influenza vaccines regarding immunogenicity and safety. A total of 1,023 healthy adults aged 18-64 y were enrolled in the study. Subjects were randomly assigned in a 1:1 ratio to receive the GC FLU® Prefilled Syringe or the GC FLU® Injection, and they were further randomized to one of 3 lots of each vaccine in a 1:1:1 ratio. In both GC FLU® Injection and GC FLU® Prefilled Syringe groups, immune responses were equivalent between lots for each of the 3 vaccine strains on day 21. The 2-sided 95% CI of GMT ratios between pairs of lots were between 0.67 and 1.5, meeting the equivalence criteria. After vaccination, all 3 criteria of the European Medicines Agency were met in both GC FLU® Injection and GC FLU® Prefilled Syringe groups. The vaccines showed tolerable safety profiles without serious adverse events. The demonstration of lot consistency, robust immunogenic responses and favorable safety profiles support the reliability of mass-manufacturing systems for the GC FLU® Injection and GC FLU® Prefilled Syringe.

Original languageEnglish
Pages (from-to)2958-2964
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume10
Issue number10
DOIs
Publication statusPublished - 2014 Oct 1

Fingerprint

Influenza Vaccines
Syringes
Vaccines
Randomized Controlled Trials
Injections
Safety
Human Influenza
Vaccination
Prefil

Keywords

  • Immunogenicity
  • Influenza vaccines
  • Lot consistency
  • Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Phase IV : Randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults. / Song, Joon-Young; Cheong, Hee-Jin; Lee, Jacob; Wie, Seong Heon; Park, Kyung Hwa; Kee, Sae Yoon; Jeong, Hye Won; Kim, Yeon Sook; Noh, Ji Yun; Choi, Wonseok; Park, Dae Won; Sohn, Jang Wook; Kim, Woo Joo.

In: Human Vaccines and Immunotherapeutics, Vol. 10, No. 10, 01.10.2014, p. 2958-2964.

Research output: Contribution to journalArticle

@article{23eee4ed601e481e998892c6ce87ad96,
title = "Phase IV: Randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults",
abstract = "Influenza vaccines are the primary method for preventing influenza and its complications. Considering the increasing demand for influenza vaccines, vaccine manufacturers are required to establish large-scale production systems. This phase IV randomized trial was conducted to evaluate the lot consistency of trivalent split influenza vaccines regarding immunogenicity and safety. A total of 1,023 healthy adults aged 18-64 y were enrolled in the study. Subjects were randomly assigned in a 1:1 ratio to receive the GC FLU{\circledR} Prefilled Syringe or the GC FLU{\circledR} Injection, and they were further randomized to one of 3 lots of each vaccine in a 1:1:1 ratio. In both GC FLU{\circledR} Injection and GC FLU{\circledR} Prefilled Syringe groups, immune responses were equivalent between lots for each of the 3 vaccine strains on day 21. The 2-sided 95{\%} CI of GMT ratios between pairs of lots were between 0.67 and 1.5, meeting the equivalence criteria. After vaccination, all 3 criteria of the European Medicines Agency were met in both GC FLU{\circledR} Injection and GC FLU{\circledR} Prefilled Syringe groups. The vaccines showed tolerable safety profiles without serious adverse events. The demonstration of lot consistency, robust immunogenic responses and favorable safety profiles support the reliability of mass-manufacturing systems for the GC FLU{\circledR} Injection and GC FLU{\circledR} Prefilled Syringe.",
keywords = "Immunogenicity, Influenza vaccines, Lot consistency, Safety",
author = "Joon-Young Song and Hee-Jin Cheong and Jacob Lee and Wie, {Seong Heon} and Park, {Kyung Hwa} and Kee, {Sae Yoon} and Jeong, {Hye Won} and Kim, {Yeon Sook} and Noh, {Ji Yun} and Wonseok Choi and Park, {Dae Won} and Sohn, {Jang Wook} and Kim, {Woo Joo}",
year = "2014",
month = "10",
day = "1",
doi = "10.4161/21645515.2014.970950",
language = "English",
volume = "10",
pages = "2958--2964",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "10",

}

TY - JOUR

T1 - Phase IV

T2 - Randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults

AU - Song, Joon-Young

AU - Cheong, Hee-Jin

AU - Lee, Jacob

AU - Wie, Seong Heon

AU - Park, Kyung Hwa

AU - Kee, Sae Yoon

AU - Jeong, Hye Won

AU - Kim, Yeon Sook

AU - Noh, Ji Yun

AU - Choi, Wonseok

AU - Park, Dae Won

AU - Sohn, Jang Wook

AU - Kim, Woo Joo

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Influenza vaccines are the primary method for preventing influenza and its complications. Considering the increasing demand for influenza vaccines, vaccine manufacturers are required to establish large-scale production systems. This phase IV randomized trial was conducted to evaluate the lot consistency of trivalent split influenza vaccines regarding immunogenicity and safety. A total of 1,023 healthy adults aged 18-64 y were enrolled in the study. Subjects were randomly assigned in a 1:1 ratio to receive the GC FLU® Prefilled Syringe or the GC FLU® Injection, and they were further randomized to one of 3 lots of each vaccine in a 1:1:1 ratio. In both GC FLU® Injection and GC FLU® Prefilled Syringe groups, immune responses were equivalent between lots for each of the 3 vaccine strains on day 21. The 2-sided 95% CI of GMT ratios between pairs of lots were between 0.67 and 1.5, meeting the equivalence criteria. After vaccination, all 3 criteria of the European Medicines Agency were met in both GC FLU® Injection and GC FLU® Prefilled Syringe groups. The vaccines showed tolerable safety profiles without serious adverse events. The demonstration of lot consistency, robust immunogenic responses and favorable safety profiles support the reliability of mass-manufacturing systems for the GC FLU® Injection and GC FLU® Prefilled Syringe.

AB - Influenza vaccines are the primary method for preventing influenza and its complications. Considering the increasing demand for influenza vaccines, vaccine manufacturers are required to establish large-scale production systems. This phase IV randomized trial was conducted to evaluate the lot consistency of trivalent split influenza vaccines regarding immunogenicity and safety. A total of 1,023 healthy adults aged 18-64 y were enrolled in the study. Subjects were randomly assigned in a 1:1 ratio to receive the GC FLU® Prefilled Syringe or the GC FLU® Injection, and they were further randomized to one of 3 lots of each vaccine in a 1:1:1 ratio. In both GC FLU® Injection and GC FLU® Prefilled Syringe groups, immune responses were equivalent between lots for each of the 3 vaccine strains on day 21. The 2-sided 95% CI of GMT ratios between pairs of lots were between 0.67 and 1.5, meeting the equivalence criteria. After vaccination, all 3 criteria of the European Medicines Agency were met in both GC FLU® Injection and GC FLU® Prefilled Syringe groups. The vaccines showed tolerable safety profiles without serious adverse events. The demonstration of lot consistency, robust immunogenic responses and favorable safety profiles support the reliability of mass-manufacturing systems for the GC FLU® Injection and GC FLU® Prefilled Syringe.

KW - Immunogenicity

KW - Influenza vaccines

KW - Lot consistency

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84921389498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921389498&partnerID=8YFLogxK

U2 - 10.4161/21645515.2014.970950

DO - 10.4161/21645515.2014.970950

M3 - Article

C2 - 25483462

AN - SCOPUS:84921389498

VL - 10

SP - 2958

EP - 2964

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 10

ER -